Madrigal Pharmaceuticals (MDGL) Competitors $288.00 +5.14 (+1.82%) As of 12:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL vs. BIIB, UTHR, INCY, BMRN, EXEL, NBIX, EXAS, RGEN, HALO, and IONSShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Neurocrine Biosciences Exact Sciences Repligen Halozyme Therapeutics Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability. Which has stronger valuation & earnings, BIIB or MDGL? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.82B1.80$1.63B$10.1311.88Madrigal Pharmaceuticals$317.38M19.79-$373.63M-$18.05-15.67 Does the MarketBeat Community prefer BIIB or MDGL? Biogen received 1358 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 68.03% of users gave Madrigal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes182471.28% Underperform Votes73528.72% Madrigal PharmaceuticalsOutperform Votes46668.03% Underperform Votes21931.97% Do institutionals & insiders hold more shares of BIIB or MDGL? 87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 22.8% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, BIIB or MDGL? Biogen has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.91, suggesting that its stock price is 191% less volatile than the S&P 500. Does the media refer more to BIIB or MDGL? In the previous week, Biogen had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 18 mentions for Biogen and 16 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.37 beat Biogen's score of 1.19 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 12 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BIIB or MDGL more profitable? Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.87% 14.98% 8.76% Madrigal Pharmaceuticals N/A -71.78%-53.25% Do analysts recommend BIIB or MDGL? Biogen currently has a consensus target price of $191.30, suggesting a potential upside of 58.92%. Madrigal Pharmaceuticals has a consensus target price of $416.33, suggesting a potential upside of 47.19%. Given Biogen's higher probable upside, equities research analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 SummaryBiogen beats Madrigal Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.28B$6.24B$5.21B$8.44BDividend YieldN/A3.01%4.99%4.18%P/E Ratio-11.288.6526.4719.72Price / Sales19.79268.82397.91117.74Price / CashN/A65.8538.3134.62Price / Book13.786.266.694.51Net Income-$373.63M$143.73M$3.22B$247.94M7 Day Performance-5.58%-0.38%0.06%3.40%1 Month Performance-11.91%4.55%5.41%11.07%1 Year Performance33.59%-7.57%13.19%5.78% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals4.6339 of 5 stars$288.00+1.8%$416.33+44.6%+34.1%$6.39B$317.38M-11.4790Positive NewsBIIBBiogen4.8959 of 5 stars$121.80-1.4%$194.56+59.7%-46.9%$17.83B$9.68B10.888,720UTHRUnited Therapeutics4.9889 of 5 stars$298.70+1.4%$392.00+31.2%+11.1%$13.47B$2.99B13.12980Positive NewsINCYIncyte4.9136 of 5 stars$62.11-0.7%$73.53+18.4%+7.2%$12.02B$4.41B230.052,320News CoveragePositive NewsBMRNBioMarin Pharmaceutical4.9941 of 5 stars$62.06+0.0%$93.45+50.6%-26.3%$11.84B$2.95B28.213,080Positive NewsEXELExelixis4.1118 of 5 stars$39.84+0.6%$37.59-5.7%+112.7%$10.98B$2.17B22.511,220Analyst ForecastOptions VolumeNews CoveragePositive NewsNBIXNeurocrine Biosciences4.9321 of 5 stars$109.75+0.1%$160.90+46.6%-14.2%$10.86B$2.36B33.361,200EXASExact Sciences4.7055 of 5 stars$53.33+3.5%$70.90+32.9%+1.6%$10.06B$2.83B-9.576,400Positive NewsRGENRepligen4.9047 of 5 stars$140.92-0.4%$173.25+22.9%-25.8%$7.91B$650.43M-276.312,020HALOHalozyme Therapeutics4.9697 of 5 stars$60.62-0.9%$62.89+3.7%+9.3%$7.49B$1.02B17.67390Analyst DowngradeIONSIonis Pharmaceuticals4.5031 of 5 stars$33.65+2.7%$56.67+68.4%-14.8%$5.35B$705.14M-11.07800Positive News Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Neurocrine Biosciences Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Ionis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDGL) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.